Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Food Effect of Single or Repeat Doses of GSK2793660 in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, and laboratory tests. A subject with a clinical abnormality or laboratory parameters outside the reference range, and which is not a part of an eligibility criterion, for the population being studied may be included only if the Investigator and GSK medical monitor consider the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures and outcome.~* Male or female between 18 and 55 years of age inclusive, at the time of signing the informed consent.~* A female subject is eligible to participate if she is of: Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation, removal of both ovaries or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea \[in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) \>21.7 International units per liter (IU/L) and oestradiol \<110 picomole per liter (pmol/L) is confirmatory\]. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods listed in the protocol if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment. For most forms of HRT, at least 2-4 weeks should elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method.~* Male subjects with female partners of child-bearing potential must agree to use one of the approved contraception methods as detailed in the protocol. This criterion must be followed from the time of the first dose of study medication until the follow-up visit.~* Body weight \>=50 Kilogram (kg) and Body Mass Index (BMI) within the range 19.9-30.0 kg/meter square (m\^2) (inclusive).~* Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.~* Based on averaged QT duration corrected for heart rate by Fridericia's formula (QTcF) values of triplicate ECGs obtained over a brief recording period: Average QTcF \<450 milliseconds (msec)~* Systolic blood pressure \<=130 millimeters of mercury (mmHg) and diastolic blood pressure 80 mmHg based on average values of triplicate blood pressure readings obtained over a brief period.~* Alanine aminotransferase (ALT), alkaline phosphatase and bilirubin \<=1.5x Upper Limit of Normal (ULN) (isolated bilirubin \>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).~Exclusion Criteria:~* Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).~* ECG finding of second or third degree heart block.~* History of regular alcohol consumption within 6 months of the study defined as: an average weekly intake of \>21 units for males or \>14 units for females. One unit is equivalent to 8 gram of alcohol: a half-pint (approximately 240 milliliter \[mL\]) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits.~* History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.~* History of sensitivity to heparin or heparin-induced thrombocytopenia.~* A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.~* Urinary cotinine or exhaled breath carbon monoxide (CO) levels indicative of current smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening.~* A positive pre-study drug/alcohol screen.~* A positive test for human immunodeficiency virus (HIV) antibody.~* Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period. Blood donation will not exceed 500 mL for the entire study.~* The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).~* Exposure to more than four new chemical entities within 12 months prior to the first dosing day.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1- Part A (Type: EXPERIMENTAL): This cohort will follow an interlocking design with Cohort 2 - Part A. Out of the 9 healthy subjects in this cohort, 3 subjects will receive placebo and 6 subjects will receive GSK2793660 according to randomization schedule in three single-dose study periods. Drug administration will be staggered over 2 days in each period. On Day 1, only 1 subject will receive GSK2793660 and 1 subject will receive placebo. The remaining subjects will be dosed on Day 2 of each treatment period assuming adequate safety from Day 1. Placebo administration and an escalation of GSK2793660 from 0.5 mg, to 3 mg, and 20 mg in the subsequent periods, will be done with a minimum washout period of 13 days between doses. If the target clinical dose is determined as being one of the doses administered to this cohort, they will have an additional study period for the administration of target clinical dose GSK2793660 following the standard Food and drug administration (FDA) high fat/high calorie meal.
- Cohort 2- Part A (Type: EXPERIMENTAL): This cohort will follow an interlocking design with Cohort 1 - Part A. Out of the 9 healthy subjects in this cohort, 3 subjects will receive placebo and 6 subjects will receive GSK2793660 according to randomization schedule in three single-dose study periods. Drug administration will be staggered over 2 days in each period. On Day 1, only 1 subject will receive GSK2793660 and 1 subject will receive placebo. The remaining subjects will be dosed on Day 2 of each treatment period assuming adequate safety from Day 1. Placebo administration and an escalation of GSK2793660 from 1 mg, to 10 mg, and 50 mg in the subsequent periods, will be done with a minimum washout period of 13 days between doses. If the target clinical dose is determined as being one of the doses administered to this cohort, they will have an additional study period for the administration of target clinical dose GSK2793660 following the standard FDA high fat/high calorie meal.
- Cohort 3- Part B (Type: EXPERIMENTAL): It is planned that up to two doses evaluated in Part A will be taken through to Part B. In this cohort, the lower dose (which will be the likely clinically efficacious dose) will be given for 14 days. The dosing frequency (once a day or twice daily) will be based on a review of the safety, tolerability, PK and PD data from Part A. It is planned that 10 subjects will receive GSK2793660 and 5 subjects will receive placebo. Subjects will be dosed on Day 1 and then on Days 3-15 (assuming once-daily dosing). If dosing is twice-daily, doses will be administered in the morning and evening from Day 1-14.
- Cohort 4- Part B (Type: EXPERIMENTAL): It is planned that up to two doses evaluated in Part A will be taken through to Part B. In this cohort, the higher dose (maximum tolerated or safe dose) will be given for 14 days. The dosing frequency (once a day or twice daily) will be based on a review of the safety, tolerability, PK and PD data from Part A. It is planned that 10 subjects will receive GSK2793660 and 5 subjects will receive placebo. Subjects will be dosed on Day 1 and then on Days 3-15 (assuming once-daily dosing). If dosing is twice-daily, doses will be administered in the morning and evening from Day 1-14. Cohort 4 will commence only after Cohort 3 is completed and data is reviewed. Also there will be no Cohort 4, if only one dose is to be evaluated in Part B.

Based on this trial design, predict the completion outcome and termination type (if applicable).